LTRN
Lantern Pharma Inc.
Next earnings Aug 11, 2026 · consensus $-0.39 EPS
Last earnings +0.3% on 2026-05-15
$3.86
▲ +5.18%$3.86▲ +25.73%
over 1Y
L $1.12EODHDH $5.32
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+5.2%
1W-0.5%
1M+16.6%
3M+244.6%
YTD+24.1%
1Y+25.7%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 7 analysts
Buy
Conservative balance sheet (liabilities/equity 0.69x).
Return on equity -262.0% · latest
Lantern Pharma Inc. shows limited reported revenue, and -262.0% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$12.6M | -$14.4M | -$17.9M | -$22.2M | -$18.0M |
| Net income | -$12.4M | -$14.3M | -$16.0M | -$20.8M | -$17.1M |
| Diluted EPS | — | -$1.31 | -$1.47 | -$1.93 | -$1.57 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$39.0M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-39.4%
FCF yield-36.1%
Quality & risk
ROIC (est.)-217.4%
Free cash flow-$15.7M
Total debt—
Net cash$4.42M
Piotroski F-Score1/6
Capital returns
Buyback yield1.2%
Dividend yield (est.)—
Shareholder yield1.2%
Shares Δ YoY+4.4%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — restated periodic report (2026-04-30). Worth a closer look.
Recent filings
all on EDGAR ↗EFFECTFiling2026-06-18open ↗S-1Filing2026-06-12open ↗8-KPeriod ending 2026-06-012026-06-02open ↗DFiling2026-05-21open ↗SCHEDULE 13D/AFiling2026-05-15open ↗8-KPeriod ending 2026-05-152026-05-15open ↗10-QPeriod ending 2026-03-312026-05-15open ↗8-KPeriod ending 2026-05-122026-05-14open ↗4Period ending 2026-05-122026-05-14open ↗4Period ending 2026-05-122026-05-14open ↗424B5Filing2026-05-14open ↗10-K/APeriod ending 2025-12-312026-04-30open ↗
Frequently asked
- Is Lantern Pharma Inc. (LTRN) a buy?
- LTRN currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.69x).
- What is Lantern Pharma Inc.'s quality score?
- LTRN scores 53.71794871794872/100 (grade C-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001763950, latest 10-Q filed 2026-05-15) · EODHD · as of 6/22/2026, 9:52:14 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.